Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
Mar 09, 2017 21:02 pm UTC| Business
Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox Gastaut Syndrome in 2H...
Finisar Announces Record Third Fiscal Quarter Revenues
Mar 09, 2017 21:02 pm UTC| Business
SUNNYVALE, Calif., March 09, 2017 -- Finisar Corporation (NASDAQ:FNSR), a global technology leader for subsystems and components for fiber optic communications, today announced financial results for its third quarter of...
Finisar Announces Record Third Fiscal Quarter Revenues
Mar 09, 2017 21:02 pm UTC| Business
SUNNYVALE, Calif., March 09, 2017 -- Finisar Corporation (NASDAQ:FNSR), a global technology leader for subsystems and components for fiber optic communications, today announced financial results for its third quarter of...
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017
Mar 09, 2017 21:01 pm UTC| Business
HOUSTON, March 09, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic...
Harvard Bioscience Reports Fourth Quarter and Year-End 2016 Results and 2017 Financial Guidance
Mar 09, 2017 21:01 pm UTC| Business
HOLLISTON, Mass., March 09, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported its financial...
AlloSure Featured in Journal of the American Society of Nephrology
Mar 09, 2017 21:01 pm UTC| Business
BRISBANE, Calif., March 09, 2017 -- CareDx, Inc.(Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions...
Flexion Reports Year-End 2016 Financial Results
Mar 09, 2017 21:01 pm UTC| Business
NDA for ZilrettaTM(FX006) filed in December 2016 and accepted by FDA in February 2017PDUFA action date set for October 6, 2017Commercialization plans on target for potential Q4 launch of ZilrettaFrederick Driscoll, Chief...